Phenotype of CD20−CD38++ PPCs compared with B cells and with normal and tumor plasma cells
| . | B cells . | PPC . | Tonsillar plasma cells . | Bone marrow plasma cells . | Plasma cells from RP . | Myeloma plasma cells . |
|---|---|---|---|---|---|---|
| CD19 | ++ | + | + | + | + | − |
| CD20 | ++ | − | − | − | − | − |
| CD21 | ++ | + weak | + weak | + weak | − | ± |
| CD22 | ++ | − | − | − | ± | − |
| CD23 | ++ | + weak | − | − | − | − |
| CD27 | ± | ++ | ++ | ++ | ND | ± |
| CD28 | − | − | − | − | ± (1%-12%) | ± |
| CD38 | ± | ++ | ++ | ++ | ++ | ++ |
| CD45 | + | + | + | ± | + | ± |
| CD49e | − | − | − | ± | − | ± |
| CD95 | ± | + | + | − | + | ± |
| CD138 | − | ± (9%-20%) | ± | + | ± (6%-50%) | + |
| HLA DR | ++ | + | + | + | + | − |
| . | B cells . | PPC . | Tonsillar plasma cells . | Bone marrow plasma cells . | Plasma cells from RP . | Myeloma plasma cells . |
|---|---|---|---|---|---|---|
| CD19 | ++ | + | + | + | + | − |
| CD20 | ++ | − | − | − | − | − |
| CD21 | ++ | + weak | + weak | + weak | − | ± |
| CD22 | ++ | − | − | − | ± | − |
| CD23 | ++ | + weak | − | − | − | − |
| CD27 | ± | ++ | ++ | ++ | ND | ± |
| CD28 | − | − | − | − | ± (1%-12%) | ± |
| CD38 | ± | ++ | ++ | ++ | ++ | ++ |
| CD45 | + | + | + | ± | + | ± |
| CD49e | − | − | − | ± | − | ± |
| CD95 | ± | + | + | − | + | ± |
| CD138 | − | ± (9%-20%) | ± | + | ± (6%-50%) | + |
| HLA DR | ++ | + | + | + | + | − |
Fluorescence staining and analysis of PPC were performed as described in “Materials and methods.” Phenotype of B cells, tonsillar plasma cells, bone marrow plasma cells, plasma cells from RP, and myeloma plasma cells were described elsewhere. For myeloma cells, when the marker was expressed by less than 10% of the patients, it was considered negative.
ND indicates not done.